What is Hoppr?
Hoppr operates at the intersection of artificial intelligence and medical diagnostics. The company provides a comprehensive infrastructure platform designed to streamline the building, fine-tuning, and deployment of AI foundation models specifically for medical imaging. By addressing the complexities of data provenance, quality management, and regulatory compliance, Hoppr enables healthcare innovators to accelerate the development of clinically validated applications. Its platform serves as a bridge between raw medical data and actionable diagnostic insights, effectively reducing the friction that often hinders the adoption of AI in hospital workflows and patient care settings.
How much funding has Hoppr raised?
Hoppr has raised a total of $31.5M across 1 funding round:
Series A
$31.5M
Series A (2025): $31.5M with participation from Greycroft Partners, Morningside Capital, PSG Equity, Kivu Ventures, Fortitude Ventures, and Health2047
Key Investors in Hoppr
Greycroft Partners
A leading venture capital firm focused on internet and mobile markets, leveraging an extensive network to help entrepreneurs build successful businesses and gain market visibility.
Morningside Capital
A private equity firm specializing in innovative liquidity and capital solutions, including secondary and portfolio financing markets for general partners.
PSG Equity
A growth-focused private equity firm that provides strategic investment services, primarily targeting the media, communications, education, and information industries.
What's next for Hoppr?
With this major strategic investment, Hoppr is poised to scale its operations and deepen its integration within the global healthcare ecosystem. The company is expected to focus on expanding its curated data repositories and enhancing its quality management systems to support broader marketing authorization efforts. As the demand for AI-driven diagnostic tools continues to rise, Hoppr's ability to provide a secure, compliant, and scalable foundation will be pivotal. Future growth strategies will likely involve strengthening partnerships with PACS vendors and health systems to ensure that their AI applications meet the rigorous standards required for widespread clinical implementation and improved patient outcomes.
See full Hoppr company page
